Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seppo W Langer

Showing results (21-30 of 115) with videos related to

Pageof 12
Sort By:
Diagnostics (Basel, Switzerland)|February 3, 2021
Prognostic Value of <sup>18</sup>F-FDG-PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current LiteratureTine Nøhr Christensen, Per Kragh Andersen, Seppo W Langer, et al.
Cancers|September 14, 2024
Recurrence Rates and Patterns after Radical Resection of Lung CarcinoidsErika Askildsen, Patrick Soldath, Seppo W Langer, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|February 2, 2024
Prognostic thresholds of fluorine-18 fluorodeoxyglucose-positron emission tomography mean and maximum standardized uptake values for survival and nodal involvement in lung neuroendocrine neoplasmsPatrick Soldath, Tina Binderup, Andreas Kjaer, et al.
Expert Review of Anticancer Therapy|April 8, 2014
PET/CT in therapy evaluation of patients with lung cancerNatasha Hemicke Langer, Tine Nøhr Christensen, Seppo W Langer, et al.
Integrative Cancer Therapies|March 25, 2015
The Impact of a Multidimensional Exercise Intervention on Physical and Functional Capacity, Anxiety, and Depression in Patients With Advanced-Stage Lung Cancer Undergoing ChemotherapyMorten Quist, Lis Adamsen, Mikael Rørth, et al.
Diagnostics (Basel, Switzerland)|February 9, 2016
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive ReviewEmma Elizabeth Ilett, Seppo W Langer, Ingrid Holst Olsen, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2021
Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patientsPatrick Soldath, Tina Binderup, Andreas Kjær, et al.
Journal of Cancer|August 27, 2014
Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomasIngrid Holst Olsen, Ulrich Knigge, Birgitte Federspiel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2022
Prospective Phase II Trial of Prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted TherapyEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2003
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposidePatricia E Schroeder, Peter Buhl Jensen, Maxwell Sehested, et al.
Pageof 12

Showing results (21-30 of 115) with videos related to

Sort By:
Pageof 12
Diagnostics (Basel, Switzerland)|February 3, 2021
Prognostic Value of <sup>18</sup>F-FDG-PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current LiteratureTine Nøhr Christensen, Per Kragh Andersen, Seppo W Langer, et al.
Cancers|September 14, 2024
Recurrence Rates and Patterns after Radical Resection of Lung CarcinoidsErika Askildsen, Patrick Soldath, Seppo W Langer, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|February 2, 2024
Prognostic thresholds of fluorine-18 fluorodeoxyglucose-positron emission tomography mean and maximum standardized uptake values for survival and nodal involvement in lung neuroendocrine neoplasmsPatrick Soldath, Tina Binderup, Andreas Kjaer, et al.
Expert Review of Anticancer Therapy|April 8, 2014
PET/CT in therapy evaluation of patients with lung cancerNatasha Hemicke Langer, Tine Nøhr Christensen, Seppo W Langer, et al.
Integrative Cancer Therapies|March 25, 2015
The Impact of a Multidimensional Exercise Intervention on Physical and Functional Capacity, Anxiety, and Depression in Patients With Advanced-Stage Lung Cancer Undergoing ChemotherapyMorten Quist, Lis Adamsen, Mikael Rørth, et al.
Diagnostics (Basel, Switzerland)|February 9, 2016
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive ReviewEmma Elizabeth Ilett, Seppo W Langer, Ingrid Holst Olsen, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2021
Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patientsPatrick Soldath, Tina Binderup, Andreas Kjær, et al.
Journal of Cancer|August 27, 2014
Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomasIngrid Holst Olsen, Ulrich Knigge, Birgitte Federspiel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2022
Prospective Phase II Trial of Prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted TherapyEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2003
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposidePatricia E Schroeder, Peter Buhl Jensen, Maxwell Sehested, et al.
Pageof 12